Trials / Terminated
TerminatedNCT00083967
Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment
A Randomized, Double-Masked, Placebo Controlled, Parallel Group, Multi-Center, Dose-Ranging Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects With Rhegmatogenous Retinal Detachment
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test if denufosol will remove the fluid build-up in the eye so that the retina can be re-attached without invasive surgery.
Detailed description
The purpose of this trial is to determine if administration of denufosol is well-tolerated and more efficacious than placebo in stimulating subretinal fluid reabsorption and retinal reattachment without surgical intervention in subjects presenting with rhegmatogenous retinal detachment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | denufosol tetrasodium (INS37217) Intravitreal Injection |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2006-04-01
- Completion
- 2006-04-01
- First posted
- 2004-06-07
- Last updated
- 2015-04-10
Locations
33 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00083967. Inclusion in this directory is not an endorsement.